{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:54:27Z","timestamp":1792637667259,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["22-PZR-06"],"award-info":[{"award-number":["22-PZR-06"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We evaluated the in vitro activity of ceftibuten-avibactam against Enterobacterales causing urinary tract infection (UTI). A total of 3216 isolates (1\/patient) were consecutively collected from patients with UTI in 72 hospitals from 25 countries in 2021 then susceptibility tested by CLSI broth microdilution. Ceftibuten-susceptible breakpoints currently published by EUCAST (\u2264\u20091\u00a0mg\/L) and CLSI (\u2264\u20098\u00a0mg\/L) were applied to ceftibuten-avibactam for comparison. The most active agents were ceftibuten-avibactam (98.4%\/99.6% inhibited at\u2009\u2264\u20091\/\u2009\u2264\u20098\u00a0mg\/L), ceftazidime-avibactam (99.6% susceptible [S]), amikacin (99.1%S), and meropenem (98.2%S). Ceftibuten-avibactam (MIC<jats:sub>50\/90<\/jats:sub>, 0.03\/0.06\u00a0mg\/L) was fourfold more potent than ceftazidime-avibactam (MIC<jats:sub>50\/90<\/jats:sub>, 0.12\/0.25\u00a0mg\/L) based on MIC<jats:sub>50\/90<\/jats:sub> values. The most active oral agents were ceftibuten (89.3%S; 79.5% inhibited at\u2009\u2264\u20091\u00a0mg\/L), levofloxacin (75.4%S), and trimethoprim-sulfamethoxazole (TMP-SMX; 73.4%S). Ceftibuten-avibactam inhibited 97.6% of isolates with an extended-spectrum \u03b2-lactamase phenotype, 92.1% of multidrug-resistant isolates, and 73.7% of carbapenem-resistant Enterobacterales (CRE) at\u2009\u2264\u20091\u00a0mg\/L. The second most active oral agent against CRE was TMP-SMX (24.6%S). Ceftazidime-avibactam was active against 77.2% of CRE isolates. In conclusion, ceftibuten-avibactam was highly active against a large collection of contemporary Enterobacterales isolated from patients with UTI and exhibited a similar spectrum to ceftazidime-avibactam. Ceftibuten-avibactam may represent a valuable option for oral treatment of UTI caused by multidrug-resistant Enterobacterales.<\/jats:p>","DOI":"10.1007\/s10096-023-04562-4","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:04:25Z","timestamp":1677024265000},"page":"453-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021)"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7022-6644","authenticated-orcid":false,"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia G.","family":"Carvalhaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"issue":"1","key":"4562_CR1","doi-asserted-by":"publisher","first-page":"ofw281","DOI":"10.1093\/ofid\/ofw281","volume":"4","author":"J Simmering","year":"2017","unstructured":"Simmering J, Tang F, Cavanaugh J, Polgreen L, Polgreen P (2017) The increase in hospitalizations for urinary tract infections and the associated costs in the United States, 1998\u20132011. Open Forum Infect Dis 4(1):ofw281. https:\/\/doi.org\/10.1093\/ofid\/ofw281","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"4562_CR2","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1086\/671740","volume":"34","author":"MD Zilberberg","year":"2013","unstructured":"Zilberberg MD, Shorr AF (2013) Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000\u20132009. Infect Control Hosp Epidemiol 34(9):940\u2013946. https:\/\/doi.org\/10.1086\/671740","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"4562_CR3","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1128\/AAC.02897-15","volume":"60","author":"GV Sanchez","year":"2016","unstructured":"Sanchez GV, Babiker A, Master RN, Luu T, Mathur A, Bordon J (2016) Antibiotic resistance among urinary isolates from female outpatients in the United States in 2003 and 2012. Antimicrob Agents Chemother 60(5):2680\u20132683. https:\/\/doi.org\/10.1128\/AAC.02897-15","journal-title":"Antimicrob Agents Chemother"},{"key":"4562_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40121-015-0095-5","volume":"4","author":"G Kahlmeter","year":"2015","unstructured":"Kahlmeter G, \u00c5hman J, Matuschek E (2015) Antimicrobial resistance of Escherichia coli causing uncomplicated urinary tract infections: a European update for 2014 and comparison with 2000 and 2008. Infect. Dis. Ther. 4:417\u2013423. https:\/\/doi.org\/10.1007\/s40121-015-0095-5","journal-title":"Infect. Dis. Ther."},{"key":"4562_CR5","unstructured":"US FDA (2016) FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. July 26, 2016.\u00a0https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain. Accessed July 2022"},{"issue":"4","key":"4562_CR6","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"American Geriatrics Society Beers Criteria Update Expert Panel","year":"2019","unstructured":"American Geriatrics Society Beers Criteria Update Expert Panel (2019) American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 67(4):674\u2013694. https:\/\/doi.org\/10.1111\/jgs.15767","journal-title":"J Am Geriatr Soc"},{"key":"4562_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/acem.14545","author":"B Faine","year":"2022","unstructured":"Faine B, Rech M, Vakkalanka P, Gross A, Brown C, Harding S, Slocum G, Zimmerman D, Zepeski A, Rewitzer S, Howington G, Campbell M, Dawson J, Treu C, Nelson L, Jones M, Flack T, Porter B, Sarangarm P, Mattson A, Bailey A, Kelly G, Talan D (2022) High prevalence of fluoroquinolone-resistant UTI among US emergency department patients diagnosed with urinary tract infection, 2018\u20132020. Acad Emerg Med. https:\/\/doi.org\/10.1111\/acem.14545","journal-title":"Acad Emerg Med"},{"issue":"2","key":"4562_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1128\/CMR.00068-15","volume":"29","author":"ME Falagas","year":"2016","unstructured":"Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ (2016) Fosfomycin. Clin Microbiol Rev 29(2):321\u2013347. https:\/\/doi.org\/10.1128\/CMR.00068-15","journal-title":"Clin Microbiol Rev"},{"key":"4562_CR9","first-page":"01","volume":"32","author":"F Candel","year":"2019","unstructured":"Candel F, David M, Lopez J (2019) New perspectives for reassessing fosfomycin: applicablity in current clinical practice. Rev Esp Quimioter 32:01\u201307","journal-title":"Rev Esp Quimioter"},{"key":"4562_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/jac\/dkac396","volume":"78","author":"N Frimodt-Moller","year":"2023","unstructured":"Frimodt-Moller N, Simonsen GS, Larsen AR, Kahlmeter G (2023) Pivmecillinam, the paradigm of an antibiotic with low resistance rates in Escherichia coli urine isolates despite high consumption. J Antimicrob Chemother 78:289\u2013295. https:\/\/doi.org\/10.1093\/jac\/dkac396","journal-title":"J Antimicrob Chemother"},{"key":"4562_CR11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2147\/IDR.S163280","volume":"11","author":"F Jansaker","year":"2018","unstructured":"Jansaker F, Frimodt-Moller N, Benfield T, Knudson J (2018) Mecillinam for the treatment of acute pyelonephritis and bacteremia caused by Enterobacteriaceae: a literature review. Infect Drug Resist 11:761\u2013771. https:\/\/doi.org\/10.2147\/IDR.S163280","journal-title":"Infect Drug Resist"},{"issue":"5","key":"4562_CR12","doi-asserted-by":"publisher","first-page":"784","DOI":"10.2165\/00003495-199447050-00006","volume":"47","author":"LR Wiseman","year":"1994","unstructured":"Wiseman LR, Balfour JA (1994) Ceftibuten. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 47(5):784\u2013808. https:\/\/doi.org\/10.2165\/00003495-199447050-00006","journal-title":"Drugs"},{"issue":"1","key":"4562_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/s0924-8579(00)00319-8","volume":"17","author":"M Perilli","year":"2001","unstructured":"Perilli M, Segatore B, Franceschini N, Gizzi G, Mancinelli A, Caravelli B, Setacci D, del Tavio-Perez MM, Bianchi B, Amicosante G (2001) Ceftibuten stability to active-site serine and metallo-beta-lactamases. Int J Antimicrob Agents 17(1):45\u201350. https:\/\/doi.org\/10.1016\/s0924-8579(00)00319-8","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"4562_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","volume":"77","author":"D Wong","year":"2017","unstructured":"Wong D, van Duin D (2017) Novel beta-lactamase inhibitors: unlocking their potential in therapy. Drugs 77(6):615\u2013628. https:\/\/doi.org\/10.1007\/s40265-017-0725-1","journal-title":"Drugs"},{"key":"4562_CR15","unstructured":"CLSI (2018) M07Ed11 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"4562_CR16","unstructured":"CLSI (2022) M100d32. Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute, Wayne, PA"},{"key":"4562_CR17","unstructured":"EUCAST (2022) v12.0 Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0, January 2022. European Committee on Antimicrobial Susceptibility Testing, V\u00e4xj\u00f6, Sweden"},{"issue":"3","key":"4562_CR18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelen MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268\u2013281. https:\/\/doi.org\/10.1111\/j.1469-0691.2011.03570.x","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"4562_CR19","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/antibiotics8030122","volume":"8","author":"B Suay-Garc\u00eda","year":"2019","unstructured":"Suay-Garc\u00eda B, P\u00e9rez-Gracia M (2019) Present and future of carbapenem-resistant Enterobacteriaceae (CRE) infections. Antibiotics (Basel) 8(3):122. https:\/\/doi.org\/10.3390\/antibiotics8030122","journal-title":"Antibiotics (Basel)"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04562-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-023-04562-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-023-04562-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T11:09:59Z","timestamp":1678360199000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-023-04562-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["4562"],"URL":"https:\/\/doi.org\/10.1007\/s10096-023-04562-4","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"assertion":[{"value":"13 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JMI Laboratories was contracted to perform services in 2018\u20132021 for AbbVie, Achaogen, Inc., Affinity Biosensors, Albany College of Pharmacy and Health Sciences, Allecra Therapeutics, Allergan, Amicrobe Advanced Biomaterials, Inc., American Proficiency Institute, AmpliPhi Biosciences Corp., Amplyx Pharma, Antabio, Arietis Corp., Arixa Pharmaceuticals, Inc., Artugen Therapeutics USA, Inc., Astellas Pharma Inc., Athelas, Becton, Basilea Pharmaceutica Ltd., Bayer AG, Becton, Beth Israel Deaconess Medical Center, BIDMC, bioMerieux, Inc., bioMerieux SA, BioVersys Ag, Boston Pharmaceuticals, Bugworks Research Inc., CEM-102 Pharmaceuticals, Cepheid, Cidara Therapeutics, Inc., Cipla, Contrafect, Cormedix Inc., Crestone, Inc., Curza, CXC7, DePuy Synthes, Destiny Pharma, Dickinson and Company, Discuva Ltd., Dr. Falk Pharma GmbH, Emery Pharma, Entasis Therapeutics, Eurofarma Laboratorios SA, Fedora Pharmaceutical, F. Hoffmann-La Roche Ltd., Fimbrion Therapeutics, US Food and Drug Administration, Fox Chase Chemical Diversity Center, Inc., Gateway Pharmaceutical LLC, GenePOC Inc., Geom Therapeutics, Inc., GlaxoSmithKline plc, Guardian Therapeutics, Hardy Diagnostics, Harvard University, Helperby, HiMedia Laboratories, ICON plc, Idorsia Pharmaceuticals Ltd., IHMA, Iterum Therapeutics plc, Janssen Research & Development, Johnson & Johnson, Kaleido Biosciences, KBP Biosciences, Laboratory Specialists, Inc., Luminex, Matrivax, Mayo Clinic, Medpace, Meiji Seika Pharma Co., Ltd., Melinta Therapeutics, Inc., Menarini, Merck & Co., Inc., Meridian Bioscience Inc., Micromyx, Microchem Laboratory, MicuRx Pharmaceutics, Inc., Mutabilis Co., N8 Medical, Nabriva Therapeutics plc, National Institutes of Health, NAEJA-RGM, National University of Singapore, North Bristol NHS Trust, Novartis AG, Novome Biotechnologies, Oxoid Ltd., Paratek Pharmaceuticals, Inc., Pharmaceutical Product Development, LLC, Polyphor Ltd., Prokaryotics Inc., QPEX Biopharma, Inc., Ra Pharmaceuticals, Inc., Rhode Island Hospital, RIHML, Roche, Roivant Sciences, Ltd., Safeguard Biosystems, Salvat, Scynexis, Inc., SeLux Diagnostics, Inc., Shionogi and Co., Ltd., SinSa Labs, Specific Diagnostics, Spero Therapeutics, Summit Pharmaceuticals International Corp., SuperTrans Medical LT, Synlogic, T2 Biosystems, Taisho Pharmaceutical Co., Ltd., TenNor Therapeutics Ltd., Tetraphase Pharmaceuticals, The Medicines Company, The University of Queensland, Theravance Biopharma, Thermo Fisher Scientific, Tufts Medical Center, Universite de Sherbrooke, University of Colorado, University of Southern California-San Diego, University of Iowa, University of Iowa Hospitals and Clinics, University of North Texas Health Science Center, University of Wisconsin, UNT System College of Pharmacy, URMC, UT Southwestern, VenatoRx, Viosera Therapeutics, Vyome Therapeutics Inc., Wayne State University, Wockhardt, Yukon Pharmaceuticals, Inc., Zai Lab, and Zavante Therapeutics, Inc. There are no speakers\u2019 bureaus or stock options to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}